IntelliPharmaCeutics (IPCI) Target Raised to $9 at Maxim Group

November 19, 2013 8:59 AM UTC Send to a Friend
Maxim Group maintained a Buy rating on IntelliPharmaCeutics International (NASDAQ: IPCI) and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login